Post-Authorization Safety Study of Hospitalization for Acute Kidney Injury in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting

INTRODUCTION: Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor approved to treat type 2 diabetes mellitus (T2DM), among other conditions. When dapagliflozin was approved in Europe for treating T2DM (2012), potential safety concerns regarding its effect on kidney function resulted in this...

Descripción completa

Detalles Bibliográficos
Autores principales: Johannes, Catherine B., Beachler, Daniel C., Layton, J. Bradley, Danysh, Heather E., Ziemiecki, Ryan, Arana, Alejandro, Dinh, Jade, Li, Ling, Calingaert, Brian, Pladevall-Vila, Manel, Hunt, Phillip R., Chen, Hungta, Karlsson, Cecilia, Johnsson, Kristina, Gilsenan, Alicia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883323/
https://www.ncbi.nlm.nih.gov/pubmed/36528670
http://dx.doi.org/10.1007/s40264-022-01263-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883323/
https://www.ncbi.nlm.nih.gov/pubmed/36528670
http://dx.doi.org/10.1007/s40264-022-01263-3

Ejemplares similares